New Data Showing Patient Care Individualized by Daxor’s Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session (NYSE MKT LLC: DXR) New York, NY, March 14, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations,...